ZTI BIOSCIENCES is a company, located at Suwon, Gyeonggi-do, South Korea. Visit their website www.zti-bio.com or LinkedIn profile for more detailed information.

ZTI BIOSCIENCES is a radiopharmaceutical developer for cancer therapy based on nano-material technology. ZTI, applying its Nano-materials tech to biotech, created a Fully-integrative platform that can integrate all components of a nuclear medicine to the TERACARRIER. ZTI tackles the fundamental weakness of radiopharmaceuticals by preventing the breakoffs of payload isotopes when injected into the body. ZTI's Tech, fundamentally prevents the escape of radioactive payloads with an unbreakable iron-grid. Furthermore, the TERACARRIER is an all-integrative platform that can utilize any Ligand or Radioisotope. It can significantly enhance the performance of the targeting ligands by increasing payload efficacy while removing side-effects coming from the free radioisotopes. TERACARRIERs are applicable to all existing radio isotopes, such as Lutetium-177 & Actinium-225, capable of preventing the issue of bone marrow accumulation from free isotopes inside the body. The core patented materials' nanotech, will allow us to unearth the full potential of Radio Isotopes, starting with Iodine-131, which mankind has only scratched its surface for the last 70 years. ZTI will standardize the advancement of Radiopharmaceuticals.

Tags : #Research